Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

August 07, 2018 16:15 ET | Source: Aileron Therapeutics, Inc.

Aileron Therapeutics Reports Second Quarter 2018 Financial Results

Preclinical in-vivo ALRN-6924 combination data with CDK4/6 inhibitors, PD-1/-L1 inhibitors, or paclitaxel (formulated as Abraxane or Taxol) all show promise in breast cancer and other cancer models...
August 02, 2018 07:00 ET | Source: Aileron Therapeutics, Inc.

Aileron Therapeutics to Present at the Canaccord Genuity 38th Annual Growth Conference

CAMBRIDGE, Mass., Aug. 02, 2018 (GLOBE NEWSWIRE) -- Aileron Therapeutics (Nasdaq:ALRN), the leader in the field of stapled peptide therapeutics for cancers and other diseases, today announced that...
July 31, 2018 07:00 ET | Source: Aileron Therapeutics, Inc.

Aileron Therapeutics to Report Second Quarter 2018 Financial Results on August 7, 2018

CAMBRIDGE, Mass., July 31, 2018 (GLOBE NEWSWIRE) -- Aileron Therapeutics (Nasdaq:ALRN), the leader in the field of stapled peptide therapeutics for cancers and other diseases, today announced that...
May 29, 2018 07:00 ET | Source: Aileron Therapeutics, Inc.

Aileron Therapeutics to Present at the Jefferies 2018 Global Healthcare Conference

CAMBRIDGE, Mass., May 29, 2018 (GLOBE NEWSWIRE) -- Aileron Therapeutics (Nasdaq:ALRN), the leader in the field of stapled peptide therapeutics for cancers and other diseases, today announced that...
May 22, 2018 05:00 ET | Source: Aileron Therapeutics, Inc.

Aileron Therapeutics Announces Publication of ALRN-6924 Nonclinical Data in T-cell Lymphomas by Researchers at Dana-Farber Cancer Institute

CAMBRIDGE, Mass., May 22, 2018 (GLOBE NEWSWIRE) -- Aileron Therapeutics (Nasdaq:ALRN), the leader in the field of stapled peptide therapeutics for cancers and other diseases, today announced the...
May 15, 2018 16:05 ET | Source: Aileron Therapeutics, Inc.

Aileron Therapeutics Announces Changes to Management

CAMBRIDGE, Mass., May 15, 2018 (GLOBE NEWSWIRE) -- Aileron Therapeutics (Nasdaq:ALRN), the clinical-stage leader in the field of stapled peptide therapeutics for cancers and other diseases, today...
May 09, 2018 16:03 ET | Source: Aileron Therapeutics, Inc.

Aileron Therapeutics Reports First Quarter 2018 Financial Results

CAMBRIDGE, Mass., May 09, 2018 (GLOBE NEWSWIRE) -- Aileron Therapeutics (Nasdaq:ALRN), the clinical-stage leader in the field of stapled peptide therapeutics for cancers and other diseases, today...
April 11, 2018 16:05 ET | Source: Aileron Therapeutics, Inc.

Aileron Therapeutics Announces Publication by Researchers at Albert Einstein College of Medicine of ALRN-6924 Nonclinical Data in Acute Myeloid Leukemia

CAMBRIDGE, Mass., April 11, 2018 (GLOBE NEWSWIRE) -- Aileron Therapeutics (NASDAQ:ALRN), the clinical stage leader in the field of stapled peptide therapeutics for cancers and other diseases, today...
April 02, 2018 16:09 ET | Source: Aileron Therapeutics, Inc.

Aileron Therapeutics Reports Fourth Quarter and Full Year 2017 Financial Results

CAMBRIDGE, Mass., April 02, 2018 (GLOBE NEWSWIRE) -- Aileron Therapeutics (NASDAQ:ALRN), the clinical-stage leader in the field of stapled peptide therapeutics for cancers and other diseases, today...
March 28, 2018 07:00 ET | Source: Aileron Therapeutics, Inc.

Aileron Therapeutics Announces Expansion of Scientific Advisory Board

CAMBRIDGE, Mass., March 28, 2018 (GLOBE NEWSWIRE) -- Aileron Therapeutics (NASDAQ:ALRN), the clinical-stage leader in the field of stapled peptide therapeutics for cancers and other diseases, today...